Grail raised approximately $325 million in a private placement to bolster commercial activities, reimbursement efforts and working capital as the company prepares regulatory filings and market expansion for its multi-cancer early-detection test. The financing included new and existing institutional investors and follows commercial and reimbursement pushes in multiple markets. Grail said the proceeds, together with other available cash and a previously announced investment from Samsung, will extend its runway toward 2030. Management positioned the raise as support for broad-scale deployment and payer engagement while the firm continues to refine clinical utility and reimbursement strategies for its circulating tumor DNA test.